Cefotaxime and Acute myeloid leukaemia aggravated - a phase IV clinical study of FDA data

Summary:

Acute myeloid leukaemia aggravated is reported only by a few people who take Cefotaxime.

The phase IV clinical study analyzes which people take Cefotaxime and have Acute myeloid leukaemia aggravated. It is created by eHealthMe based on reports of 6,414 people who have side effects while taking Cefotaxime from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 19, 2023

6,414 people reported to have side effects when taking Cefotaxime.
Among them, 5 people (0.08%) have Acute myeloid leukaemia aggravated.

What is Cefotaxime?

Cefotaxime has active ingredients of cefotaxime sodium. eHealthMe is studying from 6,433 Cefotaxime users for its effectiveness, alternative drugs and more.

What is Acute myeloid leukaemia aggravated?

Acute myeloid leukaemia aggravated (serious acute cancer in which the bone marrow makes abnormal myeloblasts) is found to be associated with 1,148 drugs and 481 conditions by eHealthMe.

Number of Cefotaxime and Acute myeloid leukaemia aggravated reports submitted per year:

Could Cefotaxime cause Acute myeloid leukaemia aggravated?

Time on Cefotaxime when people have Acute myeloid leukaemia aggravated *:

Gender of people who have Acute myeloid leukaemia aggravated when taking Cefotaxime *:

female: 80 %
male: 20 %

Age of people who have Acute myeloid leukaemia aggravated when taking Cefotaxime *:

Common drugs people take besides Cefotaxime *:

Augmentin: 3 people, 60.00%
Metronidazole: 1 person, 20.00%
Amoxicillin: 1 person, 20.00%

Common side effects people have besides Acute myeloid leukaemia aggravated *:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4 people, 80.00%
Weakness: 3 people, 60.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 60.00%
Cough: 3 people, 60.00%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 3 people, 60.00%
Pain In Extremity: 3 people, 60.00%
Diarrhea: 3 people, 60.00%
Nausea (feeling of having an urge to vomit): 3 people, 60.00%
Joint Pain: 3 people, 60.00%
Lung Disorder (lung disease): 3 people, 60.00%

Common conditions people have *:

Ventricular Extrasystoles (premature cardiac contraction): 3 people, 60.00%
Lung Disorder (lung disease): 3 people, 60.00%
Fever: 3 people, 60.00%
Diarrhea: 3 people, 60.00%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 60.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 60.00%
Clostridium Bacteraemia (presence of clostridium bacteria in the blood): 1 person, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cefotaxime and have Acute myeloid leukaemia aggravated?

Check whether Acute myeloid leukaemia aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Acute myeloid leukaemia aggravated and when was it recovered:

Acute myeloid leukaemia aggravated in Cefotaxime

Expand to all the drugs that have ingredients of cefotaxime sodium:

Acute myeloid leukaemia aggravated and drugs with ingredients of cefotaxime sodium

Alternative drugs to, pros and cons of Cefotaxime:

Cefotaxime (6,433 reports)

Common Cefotaxime side effects:

Browse all side effects of Cefotaxime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Acute myeloid leukaemia aggravated treatments and more:

Acute myeloid leukaemia aggravated (24 reports)

COVID vaccines that are related to Acute myeloid leukaemia aggravated:

Common drugs associated with Acute myeloid leukaemia aggravated:

All the drugs that are associated with Acute myeloid leukaemia aggravated:

Acute myeloid leukaemia aggravated (1,148 drugs)

Common conditions associated with Acute myeloid leukaemia aggravated:

All the conditions that are associated with Acute myeloid leukaemia aggravated:

Acute myeloid leukaemia aggravated (481 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cefotaxime sodium (the active ingredients of Cefotaxime) and Cefotaxime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.